logo

Last Update

This profile was last updated on 7/9/2009 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Rudolf Maag?

Rudolf Maag

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Chairman

Finance and Audit Committee


Chairman

Audit Committee


Chief Executive Officer

STRATEC Biomedical AG


Affiliations

Audit Committee

Board Member


STRATEC Biomedical AG

Founder


Institut Straumann AG

Board Member


Straumann Ltd

Board Member


Straumann Ltd

Chairman of Board of Directors


Geberit AG

Board Member


Education

commercial diploma


degree


Web References(29 Total References)


Straumann - International > Investor relations > Corporate governance > Board of Directors

Members: Dr h.c. Rudolf Maag (Chair), Dr Sebastian Burckhardt, Jürg Morant.


Geberit AG Annual Report 2005

Rudolf Maag (1946)The term of office for both Dr Robert Heberlein and Rudolf Maag is set to expire at the general meeting on 28 April 2006.Rudolf Maag will be stepping down from the Board of Directors.Kurt E. Feller (Chairman), Dr Robert Heberlein, Günter F. Kelm, Rudolf Maag, Klaus WeisshaarKurt E. Feller (Chairman), Günter F. Kelm, Rudolf Maag Rudolf Maag


http://dentistry.all-details.com/what-is-dentist-chair

Rudolf Maag - Chairman of the Board, Chair Finance and Audit Committee.


Geberit AG Annual Report 2005

Rudolf Maag (1946) Rudolf Maag holds a commercial diploma and graduated with the degree of an INSEAD MBA.He started his career in 1968 with UTC (Basler Handelsgesellschaft).In 1973, he joined Sandoz AG where he held various management positions in the agricultural division, among other functions, as Marketing and Sales Director USA and Head of Division Brazil.In 1986, Rudolf Maag joined Institut Straumann AG as a Director.Four years later, he founded Stratec Medical by way of a management buy-out.Following a successful Initial Public Offering in 1996, Stratec merged with the US company Synthes Ltd. to form Synthes-Stratec.Rudolf Maag became Vice Chairman of the Board of Directors and CEO.In 2000, he left Synthes-Stratec to act as an independent member of various Boards of Directors as well as a private equity investor. The term of office for both Dr Robert Heberlein and Rudolf Maag is set to expire at the general meeting on 28 April 2006.Rudolf Maag will be stepping down from the Board of Directors.The members of the Personnel Committee are Kurt E. Feller (Chairman), Günter F. Kelm and Rudolf Maag.The Audit Committee is composed of Kurt E. Feller (Chairman), Dr Robert Heberlein, Günter F. Kelm, Rudolf Maag and Klaus Weisshaar.


http://www.stratec.com/media/data_detail.asp?ID=16&From=Press

Mr Hansjörg Wyss, currently Chairman and Chief Executive Officer of SYNTHES, will assume the position of Chairman of SYNTHES-STRATEC, and Mr Rudolf Maag, currently Chief Executive Officer of STRATEC, will serve as President and Chief Executive Officer of the combined entity.In addition to Mr Rudolf Maag, the principal Executive Officers for SYNTHES-STRATEC will include Charles Hedgepeth (Vice President – USA).Mr Rudolf Maag, who currently controls 69% of the voting rights and 51% of the share capital of STRATEC, has accepted the combination terms and supports the exchange offer.The combination and the offering of SYNTHES-STRATEC shares are subject to approval by various competition authorities in both the US and Europe, to an 80% acceptance by votes and by capital of the exchange offer of all STRATEC shareholders and to other customary conditions to be published in the exchange offer documentation.It is anticipated that the combination will be completed by May 1999.Furthermore, market conditions permitting, it is currently contemplated that a secondary share offering representing approximately 10% of the shares of SYNTHES-STRATEC will be conducted within 12 months of the closing of the combination, increasing the free float of SYNTHES-STRATEC to approximately 25% of the shares outstanding.STRATEC has retained the services of Merrill Lynch & Co. to render a fairness opinion in connection with the combination.On February 23, 1999, Merrill Lynch & Co. rendered its opinion to the Board of Directors of STRATEC that subject to the assumptions and limitations set forth therein and as of the date thereof, the exchange ratio was fair, from a financial point of view, to the shareholders of STRATEC.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory